Biotech Informa is the news portal and database where industry and suppliers meet...
The Biotech Database lists in detail over 10,000 Biotech companies and resource suppliers characterised by speciality and geographical location, these include listings for biotech companies, biotech suppliers, biotech finance and biotech R&D companies.
Biotech Informa is a unique database of Biotech companies, the Biotech database covers everything from biotech companies and biotech suppliers to biotech finance and biotech R&D companies.
Our news service brings you up to the minute information about developments in the Biotech Industry including new products, clinical data, mergers and acquisitions as well as changes in regulations etc.
We keep you up to date with a worldwide list of key Biotechnology conferences, courses and meetings. We give you the opportunity to showcase your products and services to your target audience.
The Biotech databases unique feature is the ablility, once you are registered, to make your own entry and change it whenever required from your computer so the information is always up to date.
This is the web portal the Biotech Industry and all who wish to provide resources has been needing.
GSK halts execs from selling "Resveratrol"GlaxoSmithKline has ordered two of its U.S. executives to stop selling the anti-aging supplement "Resveratrol" without the company's knowledge or permission. In 2008 GSK negotiated access to Sirtis' pipeline of drugs based on Resveratrol for $720. The compound is found in red wine and research suggests that it may ramp up the metabolic activity in cells and could one day be used to treat diabetes, cancer and many other diseases. The U.K. based pharmaceutical giant ordered Cristoph Westphal and Michelle Dipp to cease selling a resveratrol dietary supplement through a nonprofit venture known as the Healthy Lifespan Institute that the two executives helped establish last year. Alectos Therapeutics & Merck - new collaborationAlectos Therapeutics Inc. have announced a research collaboration with Merck, to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer’s disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target. Under the terms of the agreement, Merck has paid Alectos an upfront payment and will fund research to include study of Alectos’ existing portfolio of compounds targeting Alzheimer’s disease. Alectos is eligible to receive a total of US $289 million in an upfront fee, research, development and regulatory milestones and tiered royalty payments on sales of any products resulting from this collaboration. New Antibiotic that will combat Drug-Resistant BacteriaNew details have been published showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments. The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections. Using an imaging technique called x-ray crystallography, a team of researchers from GlaxoSmithKline (GSK) captured a snapshot of the new compound latched on to the enzyme topoisomerase. This enzyme is part of the bacteria’s internal machinery and helps the bacteria produce proteins and replicate. Stopping this enzyme prevents the bacteria from reproducing. Medicines, known as the quinolones, that target the enzyme have been successfully used as antibiotics since 1962, however bacteria are increasingly developing resistance to this class of drugs. Vectura and GlaxoSmithKline - new agreement reachedVectura Group plc have announced that Glaxo Group Limited and GlaxoSmithKline Research & Development Limited (“GSK”) have signed a worldwide non-exclusive agreement to license some of Vectura’s dry powder drug formulation patents in relation to two late stage development compounds in GSK’s respiratory product pipeline. Under the terms of the agreement, Vectura will receive up to £20 million in up-front and milestone payments. An initial up-front payment of £10 million will be received in September 2010 with the remaining £10 million expected to be received by the time both compounds are launched. In addition, Vectura will earn royalties capped at certain levels of sales of these products. The maximum annual royalties payable to Vectura under this license agreement will be £13 million. Eli Lilly to invest $250M in Australian Biotech industryEli Lilly and Company, and other strategic US partners will create an investment fund of up to USD$250 million to back the expansion and development of the Queensland and Australian biotechnology industry. The Queensland Government is investing $25 million in the venture capital fund. Lilly will contribute up to 20 percent of the total funding, while other strategic investors will also participate. “Today represents a turning point in support for home-grown ideas and innovation,” said Premier Anna Bligh. “We have just secured a major venture capital fund with several prominent names in the US to provide the financial muscle needed to bring Queensland ideas and innovation to the commercial stage right at home in our own backyard. We have a plan to make Queensland's biotechnology industry worth $20 billion and employ 16,000 people by 2025." Novozymes and Ceres partner on biofuel cropsEnergy crop company Ceres, Inc. and Novozymes, the world’s largest enzyme provider, have entered a research collaboration to co-develop customized plant varieties and enzyme cocktails for the production of cellulosic biofuel. The companies expect to improve the process of converting biomass to fuel through more effective enzymes and higher quality energy crops in a joint optimization project that will lead to greater fuel yields, as well as lower capital and operating costs. “This is an example of how technology providers from different parts of the value chain are coming together to make cellulosic biofuel a commercial reality. Energy crops have an important role to play in the world’s future, sustainable energy mix. According to the Billion Ton Study by the US Department of Energy, one third of the total sustainably collected biomass potential from agricultural resources can come from perennial crops,” said Cynthia Bryant, Global Biomass Business Development Manager of Novozymes. |
